A scalable system for production of functional pancreatic progenitors from human embryonic stem cells.

Viacyte, Inc., Athens, Georgia, United States of America.
PLoS ONE (Impact Factor: 3.53). 05/2012; 7(5):e37004. DOI: 10.1371/journal.pone.0037004
Source: PubMed

ABSTRACT Development of a human embryonic stem cell (hESC)-based therapy for type 1 diabetes will require the translation of proof-of-principle concepts into a scalable, controlled, and regulated cell manufacturing process. We have previously demonstrated that hESC can be directed to differentiate into pancreatic progenitors that mature into functional glucose-responsive, insulin-secreting cells in vivo. In this study we describe hESC expansion and banking methods and a suspension-based differentiation system, which together underpin an integrated scalable manufacturing process for producing pancreatic progenitors. This system has been optimized for the CyT49 cell line. Accordingly, qualified large-scale single-cell master and working cGMP cell banks of CyT49 have been generated to provide a virtually unlimited starting resource for manufacturing. Upon thaw from these banks, we expanded CyT49 for two weeks in an adherent culture format that achieves 50-100 fold expansion per week. Undifferentiated CyT49 were then aggregated into clusters in dynamic rotational suspension culture, followed by differentiation en masse for two weeks with a four-stage protocol. Numerous scaled differentiation runs generated reproducible and defined population compositions highly enriched for pancreatic cell lineages, as shown by examining mRNA expression at each stage of differentiation and flow cytometry of the final population. Islet-like tissue containing glucose-responsive, insulin-secreting cells was generated upon implantation into mice. By four- to five-months post-engraftment, mature neo-pancreatic tissue was sufficient to protect against streptozotocin (STZ)-induced hyperglycemia. In summary, we have developed a tractable manufacturing process for the generation of functional pancreatic progenitors from hESC on a scale amenable to clinical entry.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Generation of surrogate sources of insulin-producing β-cells remains a goal of diabetes therapy. While most efforts have been directed at differentiating embryonic or induced pluripotent stem (iPS) cells into β-like-cells through endodermal progenitors, we have shown that gut endocrine progenitor cells of mice can be differentiated into glucose-responsive, insulin-producing cells by ablation of transcription factor Foxo1. Here we show that FOXO1 is present in human gut endocrine progenitor and serotonin-producing cells. Using gut organoids derived from human iPS cells, we show that FOXO1 inhibition using a dominant-negative mutant or lentivirus-encoded small hairpin RNA promotes generation of insulin-positive cells that express all markers of mature pancreatic β-cells, release C-peptide in response to secretagogues and survive in vivo following transplantation into mice. The findings raise the possibility of using gut-targeted FOXO1 inhibition or gut organoids as a source of insulin-producing cells to treat human diabetes.
    Nature Communications 06/2014; 5:4242. · 10.74 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Replacement of insulin-producing cells is a promising therapy for the restoration of the beta cell mass that is destroyed in patients with type 1 diabetes (T1D). However, the use of large amounts of islets per transplant, coupled with the scarcity of donor tissue, diminishes its feasibility. Here we briefly discuss current progress in developing ideal functional beta cells as well as the rationale for developing renewable sources of insulin-producing cells that can be transplanted.
    Trends in Endocrinology and Metabolism 06/2014; · 8.87 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Beta cells generated from large-scale sources can overcome current shortages in clinical islet cell grafts provided they adequately respond to metabolic variations. Pancreatic (non)endocrine cells can develop from human embryonic stem (huES-)cells following in vitro derivation to pancreatic endoderm (PE) that is subsequently implanted in immune-incompetent mice for further differentiation. Encapsulation of PE increases the proportion of endocrine cells in subcutaneous implants, with enrichment in beta cells when placed in TheraCyte-macro-devices and predominantly alpha cells when alginate-micro-encapsulated. At posttransplant week 20-30, macro-huES-implants presented higher glucose-responsive plasma C-peptide levels and a lower proinsulin over C-peptide ratio than human islet cell implants under the kidney capsule. Their ex vivo analysis showed the presence of single-hormone-positive alpha and beta cells that exhibited rapid secretory responses to increasing and decreasing glucose concentrations, similar to isolated human islet cells. Their insulin secretory amplitude was however lower, in part attributed to a lower cellular hormone content; it was associated with a lower glucose-induced insulin biosynthesis, but not with lower glucagon-induced stimulation, which together is compatible with an immature functional state of the huES-derived beta cells at PT week 20-30. These data support the therapeutic potential of macro-encapsulated huES-implants but indicate the need for further functional analysis. Their comparison with clinical-grade human islet cell grafts sets references for future development and clinical translation.
    AJP Endocrinology and Metabolism 09/2014; · 4.09 Impact Factor

Full-text (2 Sources)

Available from
Jun 5, 2014